ARTBIO

Focus: ARTBIO is a Norwegian biotech company specializing in radioligand therapy for oncology, currently in early-stage clinical development with a focused pipeline in metastatic castration-resistant prostate cancer.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About ARTBIO

AI assessmentNot Hiring

No open roles listed right now. Follow ARTBIO to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

lead Pb-212 radioligand therapy

Metastatic Castration-resistant Prostate Cancer

Phase 1

alpha radioligand therapy

Metastatic Castration-resistant Prostate Cancer

Phase 1

Clinical Trials (1)

Help build intelligence for ARTBIO

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering radioligand therapy modality offers exposure to an emerging and differentiated treatment approach in oncology
Public company status provides potential equity upside and access to capital markets
Focused pipeline in high-prevalence indication (mCRPC) with clear clinical validation pathway

Watch Out For

Zero active job openings signal minimal near-term hiring and limited career mobility
Pre-revenue stage with only two Phase 1 programs creates significant clinical and commercial execution risk
Missing financial data (cash position, runway, R&D spend) raises transparency concerns for career planning

Generated by Claude from ARTBIO's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT07214961Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1

212Pb-NG001

Metastatic Castration-resistant Prostate Cancer

Phase 1

Clinical Trials (1)

NCT05725070Phase 0/1 Study of 212Pb-NG001 in mCRPC

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline